PTCT
PTC Therapeutics, Inc.
$73.69
+14.27%
2026-05-08
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Key Fundamentals
P/E Ratio
8.19
Forward P/E
28.92
EPS (TTM)
$8.58
Revenue Growth (YoY)
-22.7%
Profit Margin
39.4%
Beta
0.53
Market Cap
$5.83B
Avg Volume (10D)
1.4M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$79.91
60D Low
$61.43
Avg Volume
1.2M
Latest Close
$73.69
Get breakout alerts for PTCT
Sign up for Breakout Scanner to receive daily notifications when PTCT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
PTC Therapeutics, Inc. (PTCT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PTCT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PTCT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.